Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.
The deal, financials of which are not being shared, is for the investigational phase 1 gene therapy HMR59, which is given as a one-and-done shot into the eye with the aim of helping preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,